To the Editor We read with great interest the study from Glass et al1 exploring the conundrum of continuation vs cessation of antiseizure medication (ASM) after acute symptomatic neonatal seizures. The study represents, to our knowledge, the largest and most systematic on the topic and is an important step toward an evidence-based approach to ASM use in this vulnerable population.
Crawford J, Gold J, Haas R. Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures. JAMA Neurol. 2022;79(1):90–91. doi:10.1001/jamaneurol.2021.4109
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.